Cytori Therapeutics (CYTX) Reports APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Funct
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.
The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company's proprietary Celution(R) System for the treatment of patients suffering from acute myocardial infarction.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company's proprietary Celution(R) System for the treatment of patients suffering from acute myocardial infarction.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Cytori to Present at the Jefferies 2012 Global Healthcare Conference on June 5
- Cepheid (CPHD) Receives FDA Approval for GeneXpert Infinity-80 System
- HeartWare (HTWR) Publishes Encouraging Data from ADVANCE in Advanced Heart Failure
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
